Epidermal Growth Factor Receptor (EGFR) Protein Overexpression, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Malignant Neoplasm of Stomach
Conditions
Keywords
Neoadjuvant chemotherapy
Brief summary
The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard chemotherapy given before and after surgery and it can be safely administered.
Detailed description
This is a randomized phase II trial with an internal control. The randomization will be a 1:2:2 randomization (control: experimental arm 1: experimental arm 2). Potentially eligible patients will be screened centrally for the HER-2 status. After confirmation of HER-2 positive disease, eligible patients will be centrally randomized through the EORTC randomization system. A minimization technique will be used for random treatment allocation between the three treatment arms. Stratification will be done by histological subtype (intestinal/non-intestinal); Korea versus Europe; stage II versus III; node positive versus node negative.
Interventions
DRUGCisplatin
DRUG5-fluorouracil or Capecitabine
DRUGTrastuzumab
DRUGPertuzumab
PROCEDUREgastrectomy
D2 gastrectomy
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven, gastric or gastroesophageal (GE)-junction adenocarcinoma (Siewert I-III) * Patient medically fit for gastrectomy/oesophagogastrectomy as decided by the investigator * Age ≥ 18 years * WHO performance status 0 - 1 * HER-2 overexpression * Amenable to gastrectomy/oesophagectomy * The cardiac ejection fraction (LVEF), as determined by echocardiography, multiple gated acquisition scan (MUGA) or cardiac MRI should be at least 50 % * Adequate organ function * written informed consent * For women who are not postmenopausal (\> 12 months of non-therapy induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 12 months after the last treatment dose * For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 12 months after the last dose of study treatment. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods for contraception.
Exclusion criteria
* Absence of distant metastases on CT scan of thorax and abdomen * prior chemo- or antibody therapy * history of significant cardiac disease * current uncontrolled hypertension * known hypersensitivity to the components of trastuzumab, pertuzumab, cisplatin, 5-follow-up or capecitabine * known dihydropyrimidine dehydrogenase (DPD) deficiency * ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine * chronic treatment with high-dose intravenous corticosteroids * previous malignancy within the last 5 years, with the exception of adequately treated cervical carcinoma in situ, localized non-melanoma skin cancer, or other curatively treated cancer without impact on the patient's overall prognosis according to the judgment of the investigator. * psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * pregnant or breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Near Complete Pathological Response Rate | After 3 cycles (21 days) of neoadjuvant chemotherapy | To increase the major pathological response rate (\< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer. |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate | At the time of surgery |
| Distant failure | At the time of surgery and at 5 years |
| Progression-free survival | 5 years after LPI |
| Locoregional failure | At the time of surgery and at 5 years |
| Overall survival | 5 years after LPI |
| Toxicity | 5 years after LPI |
| Recurrence-free survival | 5 years after LPI |
Countries
Belgium, Estonia, France, Germany, Italy, Netherlands, Norway, Portugal, Singapore, South Korea, Spain, Switzerland, United Kingdom
Outcome results
None listed